

## IRLAB receives approval from the Finnish MPA (Fimea)

IRLAB Therapeutics AB has now received approval from Fimea (the Finnish MPA) and the Ethics Committee at the University hospital in Turku to conduct the Phase II clinical trial with IRL752 in Finland. On August 25, 2017, IRLAB received approval from the Swedish MPA to start the study in Sweden.

"It is highly pleasing that yet another Competent Authority, the Finnish MPA, has reviewed our candidate drug IRL752 and given their clinical trial approval. Now the study can recruit patients in both Sweden and Finland. In addition, we get to collaborate with highly skilled Finnish experts with vast experience of Parkinson's disease" says Joakim Tedroff, IRLAB's chief medical officer, CMO.

The randomized, double-blind, placebo controlled Phase II study is designed to study effects of IRL752 on cognitive and motor symptoms in patients with Parkinson's disease and dementia. The primary objective is to study safety and tolerability of IRL752 in this patient population.

### For further information

Nicholas Waters, CEO  
Phone: +46 730 75 77 01  
E-mail: [nicholas.waters@irlab.se](mailto:nicholas.waters@irlab.se)

Joakim Tedroff, CMO  
Phone: +46 70 760 16 91  
E-mail: [joakim.tedroff@irlab.se](mailto:joakim.tedroff@irlab.se)

This information is information that IRLAB Therapeutics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:45 CET on October 5, 2017.

FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North Premier.

### About IRLAB

IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson's disease and dementia.

IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson's disease. IRLAB also has additional programs in pre-clinical stages.

IRLAB's research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.

IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.

For more information, please visit [www.irlab.se](http://www.irlab.se).